Seokhun Yang

Seokhun Yang

Auto-generated profile, based on publicly available information

Seokhun Yang

Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul National University of College of Medicine, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
DHDoyeon Hwang
Doyeon Hwang
JLJoo Myung Lee
Joo Myung Lee
SYSeokhun Yang
Seokhun Yang
MCMineok Chang
Mineok Chang
JZJinlong Zhang
Jinlong Zhang
BKBon-Kwon Koo
Bon-Kwon Koo

1 December 2022 in Radiology
Verified
Journal Article
Closed access
SYSeokhun Yang
Seokhun Yang
MHMasahiro Hoshino
Masahiro Hoshino
BKBon-Kwon Koo
Bon-Kwon Koo
TYTaishi Yonetsu
Taishi Yonetsu
JZJinlong Zhang
Jinlong Zhang
JNJagat Narula
Jagat Narula
High-risk plaque features and plaque burden at coronary CT angiography were associated with cardiovascular events independent of coronary hemodynamic flow parameters. Background Plaque assessments with coronary CT angiography (CCTA) and coronary flow indexes have prognostic implications. Purpose To investigate the association and additive prognostic value of pla...

1 January 2021 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
DHDoyeon Hwang
Doyeon Hwang
SYSeokhun Yang
Seokhun Yang
JZJinlong Zhang
Jinlong Zhang
BKBon-Kwon Koo
Bon-Kwon Koo
Korean Circulation Journal 대한심장학회지 순환기 Hwang D, et al. Korean Circ J. 2020 Oct;51:e37. https://doi.org/10.4070/kcj.2020.0548

1 January 2023 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
SYSeokhun Yang
Seokhun Yang
BKBon-Kwon Koo
Bon-Kwon Koo
Yang S, et al. Korean Circ J. 2023 Jul;53:e53. https://doi.org/10.4070/kcj.2023.0117

19 November 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
TRTae‐Min Rhee
Tae‐Min Rhee
YJYunmi Ji
Yunmi Ji
SYSeokhun Yang
Seokhun Yang
HLHeesun Lee
Heesun Lee
JPJun‐Bean Park
Jun‐Bean Park
SLSeung-Pyo Lee
Seung-Pyo Lee
Background: Whether genetic susceptibility to cardiovascular diseases (CVDs) enhances the vulnerability to adverse cardiovascular outcomes by air pollution is unknown. We assessed the combined effect of air pollution and genetic predispositions on CVD risk. Methods and Results: From the UK Biobank cohort, we selected genetically unrelated White British participants without CVD. Levels of ambient particulate matter with a diameter of <2.5 μm (PM 2.5 ) and <10 μm were estimated using land use regression models. An individual's genetic predisposition to CVDs was determined by polygenic risk scores for coronary artery disease, myocardial infarction, stroke, ischemic stroke, heart failure, and atrial fibrillation. We stratified mortality and CVD risk by PM 2.5 exposure across high and low genetic risk groups. A total of 249 082 participants (aged 56.9±8.0 years, 46.8% men) were followed for a median of 10.8 years. The combined effect of PM 2.5 exposure and the genetic predisposition of CVD demonstrated the highest risk of cardiovascular death in the high genetic risk group with the greatest PM 2.5 exposure (adjusted hazard ratios ranging from 1.73 to 2.12 across the polygenic risk score of each CVD). The combination of higher exposure to ambient PM 2.5 and high genetic risk was associated with higher incidence of all CVDs, although no significant interactions were observed between genetic risk and PM 2.5 exposure on cardiovascular death or CVD events. Conclusions: A combination of greater PM 2.5 exposure and higher genetic predisposition to particular CVDs was modestly associated with elevated risks of cardiovascular death and CVDs. Not only alleviating PM 2.5 exposure in the general population but also implementing individualized preventive approach for those at high genetic risk might be beneficial.

1 May 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
JHJung-Kyu Han
Jung-Kyu Han
KLKeehwan Lee
Keehwan Lee
SPSang-Hyeon Park
Sang-Hyeon Park
SYSeokhun Yang
Seokhun Yang
DHDoyeon Hwang
Doyeon Hwang
HKHyoSoo Kim
HyoSoo Kim
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) remains unclear. We aim to investigate the efficacy and safety of 3 to 6 months of DAPT over 12 months after complex PCI. METHODS: A post hoc analysis of the HOST-IDEA (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Coronary Intervention With Next-Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy) randomized trial which enrolled patients undergoing PCI with third-generation drug-eluting stents was performed. Complex PCI was defined by any of the following: ≥3 stents implanted, ≥3 lesions treated, bifurcation PCI with 2-stenting, total stent length ≥60 mm, left main PCI, or heavy calcification. The major end points were target lesion failure, a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization for ischemic outcomes, and major bleeding, defined as BARC (Bleeding Academic Research Consortium) type 3 or 5, for bleeding outcomes at 12 months. RESULTS: Among 1992 patients, 624 underwent complex PCI. The complex PCI group had clinical features associated with high bleeding risk. A shortened DAPT duration did not increase the risk of target lesion failure, with hazard ratios of 0.818 (95% CI, 0.403–1.659) for the complex PCI group and 1.282 (95% CI, 0.506–3.249) for the noncomplex PCI group ( P interaction =0.451). Conversely, it decreased the risk of major bleeding in the complex PCI group (hazard ratio, 0.269 [95% CI, 0.075–0.965]), but not in the noncomplex PCI group (hazard ratio, 1.534 [95% CI, 0.627–3.754], showing a significant interaction; P interaction =0.029). CONCLUSIONS: In patients undergoing complex PCI with a third-generation drug-eluting stent, a 3- to 6-month duration of DAPT was associated with a reduced risk of bleeding without an increased risk of ischemic events compared with 12-month DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02601157.